Financial disclosure records show that members of the vaccine safety panel fired by HHS Secretary RFK Jr. had financial ties to the pharmaceutical industry.

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

Arizona health officials reported the state’s first measles cases of the year, four Navajo County individuals who were not ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Merck (NYSE:MRK) experienced a 4% price move over the last month, driven by crucial developments in its product offerings. The FDA approval of ENFLONSIA for RSV prevention and the successful clinical ...

The CDC’s Advisory Committee on Immunization Practices is expected to meet later in June to issue recommendations for use.

Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S. Health Secretary Robert F. Kennedy Jr.'s ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.